121 related articles for article (PubMed ID: 38143770)
21. Novel immune-related gene signature for risk stratification and prognosis prediction in ovarian cancer.
Fei H; Han X; Wang Y; Li S
J Ovarian Res; 2023 Oct; 16(1):205. PubMed ID: 37858138
[TBL] [Abstract][Full Text] [Related]
22. CD4+ conventional T cells-related genes signature is a prognostic indicator for ovarian cancer.
Hua T; Liu DX; Zhang XC; Li ST; Yan P; Zhao Q; Chen SB
Front Immunol; 2023; 14():1151109. PubMed ID: 37063862
[TBL] [Abstract][Full Text] [Related]
23. Identification and validation of a novel signature as a diagnostic and prognostic biomarker in colorectal cancer.
Wang D; Liufu J; Yang Q; Dai S; Wang J; Xie B
Biol Direct; 2022 Nov; 17(1):29. PubMed ID: 36319976
[TBL] [Abstract][Full Text] [Related]
24. A signature based on glycosyltransferase genes provides a promising tool for the prediction of prognosis and immunotherapy responsiveness in ovarian cancer.
Xu X; Wu Y; Jia G; Zhu Q; Li D; Xie K
J Ovarian Res; 2023 Jan; 16(1):5. PubMed ID: 36611197
[TBL] [Abstract][Full Text] [Related]
25. A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer.
Wang H; Liu J; Yang J; Wang Z; Zhang Z; Peng J; Wang Y; Hong L
Front Immunol; 2022; 13():943389. PubMed ID: 36003381
[TBL] [Abstract][Full Text] [Related]
26. Ovarian cancer subtypes based on the regulatory genes of RNA modifications: Novel prediction model of prognosis.
Zheng P; Li N; Zhan X
Front Endocrinol (Lausanne); 2022; 13():972341. PubMed ID: 36545327
[TBL] [Abstract][Full Text] [Related]
27. Distinct transcriptional programs stratify ovarian cancer cell lines into the five major histological subtypes.
Barnes BM; Nelson L; Tighe A; Burghel GJ; Lin IH; Desai S; McGrail JC; Morgan RD; Taylor SS
Genome Med; 2021 Sep; 13(1):140. PubMed ID: 34470661
[TBL] [Abstract][Full Text] [Related]
28. Systematic analysis of the relationship between ovarian cancer prognosis and alternative splicing.
Zhang D; Zou D; Deng Y; Yang L
J Ovarian Res; 2021 Sep; 14(1):120. PubMed ID: 34526089
[TBL] [Abstract][Full Text] [Related]
29. Construction and validation of a transcription factors-based prognostic signature for ovarian cancer.
Cheng Q; Li L; Yu M
J Ovarian Res; 2022 Feb; 15(1):29. PubMed ID: 35227285
[TBL] [Abstract][Full Text] [Related]
30. Identifying the Role of Oxidative Stress-Related Genes as Prognostic Biomarkers and Predicting the Response of Immunotherapy and Chemotherapy in Ovarian Cancer.
Liu Q; Yang X; Yin Y; Zhang H; Yin F; Guo P; Zhang X; Sun C; Li S; Han Y; Yang Z
Oxid Med Cell Longev; 2022; 2022():6575534. PubMed ID: 36561981
[TBL] [Abstract][Full Text] [Related]
31. Identification of metabolism-associated molecular subtype in ovarian cancer.
Liu X; Wu A; Wang X; Liu Y; Xu Y; Liu G; Liu L
J Cell Mol Med; 2021 Oct; 25(20):9617-9626. PubMed ID: 34523782
[TBL] [Abstract][Full Text] [Related]
32. Machine learning and bioinformatics models to identify gene expression patterns of ovarian cancer associated with disease progression and mortality.
Hossain MA; Saiful Islam SM; Quinn JMW; Huq F; Moni MA
J Biomed Inform; 2019 Dec; 100():103313. PubMed ID: 31655274
[TBL] [Abstract][Full Text] [Related]
33. Identification of immune microenvironment subtypes that predicted the prognosis of patients with ovarian cancer.
Wang X; Li X; Wang X
J Cell Mol Med; 2021 Apr; 25(8):4053-4061. PubMed ID: 33675171
[TBL] [Abstract][Full Text] [Related]
34. Identification and Analysis of Gene Biomarkers for Ovarian Cancer.
Wang X; Xie C; Lu C
Genet Test Mol Biomarkers; 2024 Feb; 28(2):70-81. PubMed ID: 38416665
[No Abstract] [Full Text] [Related]
35. Prognostic values and prospective pathway signaling of MicroRNA-182 in ovarian cancer: a study based on gene expression omnibus (GEO) and bioinformatics analysis.
Li Y; Li L
J Ovarian Res; 2019 Nov; 12(1):106. PubMed ID: 31703725
[TBL] [Abstract][Full Text] [Related]
36. Investigating subtypes of lung adenocarcinoma by oxidative stress and immunotherapy related genes.
Duan G; Huang C; Zhao J; Zhang Y; Zhao W; Dai H
Sci Rep; 2023 Nov; 13(1):20930. PubMed ID: 38017020
[TBL] [Abstract][Full Text] [Related]
37. A novel risk score system for assessment of ovarian cancer based on co-expression network analysis and expression level of five lncRNAs.
Zhao Q; Fan C
BMC Med Genet; 2019 Jun; 20(1):103. PubMed ID: 31182053
[TBL] [Abstract][Full Text] [Related]
38. Integrative analysis of cuproptosis-associated genes for predicting immunotherapy response in single-cell and multi-cohort studies.
Li H; Wang Y; Li G; Xiong J; Qin L; Wen Q; Yue C
J Gene Med; 2024 Jan; 26(1):e3600. PubMed ID: 37776237
[TBL] [Abstract][Full Text] [Related]
39. Comprehensive analyses of mitophagy-related genes and mitophagy-related lncRNAs for patients with ovarian cancer.
Zheng J; Jiang S; Lin X; Wang H; Liu L; Cai X; Sun Y
BMC Womens Health; 2024 Jan; 24(1):37. PubMed ID: 38218807
[TBL] [Abstract][Full Text] [Related]
40. HIF-2α-dependent TGFBI promotes ovarian cancer chemoresistance by activating PI3K/Akt pathway to inhibit apoptosis and facilitate DNA repair process.
Ma S; Wang J; Cui Z; Yang X; Cui X; Li X; Zhao L
Sci Rep; 2024 Feb; 14(1):3870. PubMed ID: 38365849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
